

JF  
Gov 11645

DOCKET NO. 43016-A-PCT-US/JPW/SHS

In re application of: Philip Livingston and Friedhelm Helling

Serial No.: 08/196,154

JUL 26 1999

Group Art Unit: 1806

Filed:

November 16, 1998

Examiner: A. Caputa

For: GANGLIOSIDE-KLH CONJUGATE VACCINES WITH QS-21

HONORABLE ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

July 21, 1999

RECEIVED  
TECH CENTER 1600/2900  
JUL 29 AM 10:49

S I R:

Transmitted herewith is an amendment to the above-identified application.

- Small entity status of this application under 37 C.F.R. § 1.9 and § 1.27 has been established by a verified statement previously submitted.
- a verified statement to establish small entity status under 37 C.F.R. § 1.9 and § 1.27 is enclosed.
- No additional fee is required.

The filing fee is calculated as follows:

	NUMBER AFTER AMEND- MENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	NUMBER OF EXTRA CLAIMS PRESENTED	RATE		FEE	
				SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTITY
Total Claims	28	- * 25	= *** 3	x 9	18	= 27	0
Independent Claims	12	- ** 3	= *** 9	x 39	78	= 351	0
Multiple Dependent Claims(s) Presented		Yes <input checked="" type="checkbox"/> No		130	260	0	0
For First Time:				TOTAL ADDITIONAL \$ 378.00 FEE			

\*If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.

\*\*If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

\*\*\*If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than "0", write "0" in the space.

Applicants: Philip O. Livingston and Friedhelm Helling  
Serial No.: 08/196,154  
Filed: November 16, 1995

Amendment Transmittal Letter  
Page 2

The "HIGHEST NUMBER PREVIOUSLY PAID FOR" (Total or Independent) is the highest of the "NUMBER AFTER AMENDMENT" in any prior amendment or the number of claims as originally filed.

Please charge Deposit Account No. \_\_\_\_\_  
in the amount of \$\_\_\_\_\_.

A check in the amount of \$ 1,683.00 is enclosed.

The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-3125. Three copies of this sheet are enclosed.

Any filing fees under 37 C.F.R. §1.16 for the presentation of extra claims.

Any patent application processing fees under 37 C.F.R. §1.17.

Respectfully submitted,

*Albert Wai-Kit Chan*

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

*Albert Wai-Kit Chan*

7/21/99

Albert Wai-Kit Chan  
Reg. No. 36,479

Date

John P. White  
Registration No. 28,678  
Albert Wai-Kit Chan  
Registration No. 36,479  
Attorneys for Applicant(s)  
Cooper & Dunham, LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#19 7/29/99  
T.Gray

Applicants : Philip O. Livingston and Friedhelm Helling

U.S. Serial No.: 08/196,154 Group Unit: 1806

Filed November 16, 1995 Examiner: A. Caputa

For : GANGLIOSIDE-KLH CONJUGATE VACCINES WITH QS-



1185 Avenue of the Americas  
New York, New York 10036  
July 21, 1999

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

AMENDMENT IN RESPONSE TO THE JUNE 19, 1998  
FINAL OFFICE ACTION AND SUBMITTED AS A FIRST SUBMISSION

This Amendment is submitted in response to a June 18, 1998 Final Office Action issued by the United States Patent and Trademark Office and as a first submission pursuant to a Communication Requesting Withdrawal of Finality under 37 C.F.R. 1.129(a) of the an June 18, 1998 Final Office Action and Petition for a Five Month Extension of Time. Accordingly, this Amendment is being timely filed.

Please amend the subject application as follows:

In the claims:

Please amend claim 69 under the provisions of 37 C.F.R. § 1.121(b) by deleting the bracketed material and inserting the underlined material. Please add new claims 87-96.

--69. (Amended) A composition comprising a GM2 or a GD2 ganglioside conjugated through the ceramide portion of the ganglioside to Keyhole Limpet Hemocyanin or a derivative thereof and a carbohydrate derivable from the bark of a Quillaja saponaria Molina tree, the